Search

Your search keyword '"Majhail, Navneet"' showing total 1,952 results
Start Over Author "Majhail, Navneet"
1,952 results on '"Majhail, Navneet"'

1. International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update

Author

Rotz, Seth J., Bhatt, Neel S., Hamilton, Betty K., Duncan, Christine, Aljurf, Mahmoud, Atsuta, Yoshiko, Beebe, Kristen, Buchbinder, David, Burkhard, Peggy, Carpenter, Paul A., Chaudhri, Naeem, Elemary, Mohamed, Elsawy, Mahmoud, Guilcher, Gregory M. T., Hamad, Nada, Karduss, Amado, Peric, Zinaida, Purtill, Duncan, Rizzo, Douglas, Rodrigues, Morgani, Ostriz, Maria Belén Rosales, Salooja, Nina, Schoemans, Helene, Seber, Adriana, Sharma, Akshay, Srivastava, Alok, Stewart, Susan K., Baker, K. Scott, Majhail, Navneet S., and Phelan, Rachel

Published
2024
Full Text
View/download PDF

3. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Author

Locke, Frederick L., Siddiqi, Tanya, Jacobson, Caron A., Ghobadi, Armin, Ahmed, Sairah, Miklos, David B., Perales, Miguel-Angel, Munoz, Javier, Fingrut, Warren B., Pennisi, Martina, Gauthier, Jordan, Shadman, Mazyar, Gowda, Lohith, Mirza, Abu-Sayeef, Abid, Muhammad Bilal, Hong, Sanghee, Majhail, Navneet S., Kharfan-Dabaja, Mohamed A., Khurana, Arushi, Badar, Talha, Lin, Yi, Bennani, N. Nora, Herr, Megan M., Hu, Zhen-Huan, Wang, Hai-Lin, Baer, Anjani, Baro, Elande, Miao, Harry, Spooner, Clare, Xu, Hairong, and Pasquini, Marcelo C.

Published
2024
Full Text
View/download PDF

7. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Author

Metheny, Leland L., Sobecks, Ronald, Cho, Christina, Fu, Pingfu, Margevicius, Seunghee, Wang, Jiasheng, Ciarrone, Lisa, Kopp, Shelby, Convents, Robin D., Majhail, Navneet, Caimi, Paolo F., Otegbeye, Folashade, Cooper, Brenda W., Gallogly, Molly, Malek, Ehsan, Tomlinson, Benjamin, Gerds, Aaron T., Hamilton, Betty, Giralt, Sergio, Perales, Miguel-Angel, and de Lima, Marcos

Published
2024
Full Text
View/download PDF

8. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Author

Aldoss, Ibrahim, Roloff, Gregory W., Faramand, Rawan, Kopmar, Noam E., Lin, Chenyu, Advani, Anjali S., Dekker, Simone E., Gupta, Vishal K., O'Connor, Timothy E., Jeyakumar, Nikeshan, Muhsen, Ibrahim N., Valtis, Yannis, Zhang, Amy, Miller, Katharine, Sutherland, Katherine, Dykes, Kaitlyn C., Ahmed, Mohamed, Chen, Evan, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Connor, Matthew, O'Dwyer, Kristen M., Hill, LaQuisa C., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian, Leonard, Jessica T., Frey, Noelle V., Park, Jae H., Luskin, Marlise R., Bachanova, Veronika, Galal, Ahmed, Bishop, Michael R., Stock, Wendy, Cassaday, Ryan D., Pullarkat, Vinod, Shah, Bijal D., and Muffly, Lori S.

Published
2024
Full Text
View/download PDF

9. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States

Author

Bhatt, Neel S, Brazauskas, Ruta, Salit, Rachel B, Syrjala, Karen, Bo-Subait, Stephanie, Tecca, Heather, Badawy, Sherif M, Baker, K Scott, Beitinjaneh, Amer, Bejanyan, Nelli, Byrne, Michael, Dias, Ajoy, Farhadfar, Nosha, Freytes, César O, Ganguly, Siddhartha, Hashmi, Shahrukh, Hayashi, Robert J, Hong, Sanghee, Inamoto, Yoshihiro, Jamani, Kareem, Kasow, Kimberly A, Khera, Nandita, Krem, Maxwell M, Lazarus, Hillard M, Lee, Catherine J, Lee, Stephanie, Majhail, Navneet S, Malone, Adriana K, Marks, David I, Mau, Lih-Wen, Mayo, Samantha J, Muffly, Lori S, Nathan, Sunita, Nishihori, Taiga, Page, Kristin M, Preussler, Jaime, Rangarajan, Hemalatha G, Rotz, Seth J, Salooja, Nina, Savani, Bipin N, Schears, Raquel, Schechter-Finkelstein, Tal, Schiller, Gary, Shah, Ami J, Sharma, Akshay, Wang, Trent, Wirk, Baldeep, Battiwalla, Minoo, Schoemans, Hélène, Hamilton, Betty, Buchbinder, David, Phelan, Rachel, and Shaw, Bronwen

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Transplantation, Clinical Research, Rehabilitation, Behavioral and Social Science, Quality Education, Female, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Return to Work, Survivors, Transplantation, Homologous, United States, Young Adult, Hematopoietic cell transplantation, Return to work, Quality of life, Young adult, Immunology, Cardiovascular medicine and haematology
Abstract

Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return to work post-HCT. Work-related outcomes in this population remain understudied, however. We conducted this study to assess the post-HCT work status of survivors of allogeneic HCT who underwent HCT as YAs and to analyze the patient-, disease-, and HCT-related factors associated with their work status at 1 year post-HCT. Using Center for International Blood and Marrow Transplant Research data, we evaluated the post-HCT work status (full-time, part-time work, unemployed, or medical disability) of 1365 YA HCT survivors who underwent HCT between 2008 and 2015. Percentages of work status categories were reported at 4 time points: 6 months, 1 year, 2 years, and 3 years post-HCT. Percentages of post-HCT work status categories at the 1-year time point were also described in relation to survivors' pre-HCT work status categories. Factors associated with 1-year post-HCT work status (full-time or part-time work) were examined using logistic regression. From 6 months to 3 years post-HCT, the percentage of survivors working full-time increased from 18.3% to 50.7% and the percentage working part-time increased from 6.9% to 10.5%. Of patients in full-time work pre-HCT, 50% were unemployed or on medical disability at 1 year post-HCT. Female sex (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.40 to 0.77), HCT Comorbidity Index score ≥3 (OR, 0.57; 95% CI, 0.39 to 0.82), pre-HCT unemployment (OR, 0.37; 95% CI, 0.24 to 0.56), medical disability (OR, 0.44; 95% CI, 0.28 to 0.70), development of grade III-IV acute graft-versus-host disease (OR, 0.52; 95% CI, 0.34 to 0.80), and relapse within 1 year post-HCT (OR, 0.34; 95% CI, 0.21 to 0.56) were associated with a lower likelihood of employment at 1 year post-HCT. Compared with myeloablative conditioning (MAC) with total body irradiation (TBI), MAC without TBI (OR, 1.71; 95% CI, 1.16 to 2.53) was associated with a greater likelihood of employment at 1 year post-HCT. Graduate school-level education (OR, 2.47; 95% CI, 1.49 to 4.10) was also associated with a greater likelihood of employment at 1 year post-HCT. Although the work status among YA HCT survivors continued to improve over time, a substantial subset became or remained unemployed or on medical disability. These findings underscore the need for effective interventions to support return to work in this population.

Published
2021

10. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Al Malki, Monzr, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, Van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Blood, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.

Published
2021

13. Transplantation and Cellular Therapy

Author

Majhail, Navneet S., De Lima, Marcos, Aljurf, Mahmoud, editor, Majhail, Navneet S., editor, Koh, Mickey B.C., editor, Kharfan-Dabaja, Mohamed A., editor, and Chao, Nelson J., editor

Published
2022
Full Text
View/download PDF

14. The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond.

Author

Banerjee, Rahul, Kelkar, Amar, Logan, Aaron, Majhail, Navneet, and Pemmaraju, Naveen

Subjects
COVID-19, Conferences, Disease-specific hashtags, Social media, Twitter, Biomedical Research, COVID-19, Congresses as Topic, Hematologic Neoplasms, Humans, Interdisciplinary Communication, International Cooperation, Mentors, Scholarly Communication, Social Media, Videoconferencing
Abstract

PURPOSE OF REVIEW: The coronavirus disease 2019 (COVID-19) pandemic has had profound impacts upon scientific discourse in our field, most prominently through the abrupt transition of malignant hematology conferences to all-digital formats. These virtual components will likely be incorporated into future iterations of these conferences even as in-person attendance is reincorporated. In this review, we discuss ways in which usage of the social networking platform Twitter has expanded in the past year during virtual conferences as a method to facilitate-and, in some ways, democratize-information flow and professional networking. RECENT FINDINGS: Emerging Twitter-based tools in malignant hematology include presenter-developed #tweetorials, conference-specific poster walks, and disease-specific online journal clubs. Twitter is also increasingly being used for networking across institutional and international lines, allowing for conversations to continue year-round as a first step toward multicenter collaborations as well as in-person #tweetups at subsequent meetings. The ability of Twitter to enable uninterrupted information exchange has reinforced its central role in medical and scientific communication in a way that will certainly outlive the COVID-19 pandemic.

Published
2021

17. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Author

Hong, Sanghee, Brazauskas, Ruta, Hebert, Kyle M, Ganguly, Siddhartha, Abdel‐Azim, Hisham, Diaz, Miguel Angel, Beattie, Sara, Ciurea, Stefan O, Szwajcer, David, Badawy, Sherif M, Gratwohl, Alois A, LeMaistre, Charles, Aljurf, Mahmoud DSM, Olsson, Richard F, Bhatt, Neel S, Farhadfar, Nosha, Yared, Jean A, Yoshimi, Ayami, Seo, Sachiko, Gergis, Usama, Beitinjaneh, Amer M, Sharma, Akshay, Lazarus, Hillard, Law, Jason, Ulrickson, Matthew, Hashem, Hasan, Schoemans, Hélène, Cerny, Jan, Rizzieri, David, Savani, Bipin N, Kamble, Rammurti T, Shaw, Bronwen E, Khera, Nandita, Wood, William A, Hashmi, Shahrukh, Hahn, Theresa, Lee, Stephanie J, Rizzo, J Douglas, Majhail, Navneet S, and Saber, Wael

Subjects
Hematology, Cancer, Clinical Research, Prevention, Transplantation, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Community Health Planning, Female, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Public Health, Risk Factors, Transplantation, Homologous, Treatment Outcome, United States, Young Adult, allogeneic transplant, community health, hematopoietic cell transplantation, survival, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.MethodsThis study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.ResultsThe median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.ConclusionsPatients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.

Published
2021

19. Driving Distance and Patient-Reported Outcomes in Hematopoietic Cell Transplantation Survivors

Author

Banerjee, Rahul, Yi, Jean C, Majhail, Navneet S, Jim, Heather SL, Uberti, Joseph, Whalen, Victoria, Loren, Alison W, and Syrjala, Karen L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Transplantation, Clinical Research, Adult, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Patient Reported Outcome Measures, Survivors, Geographic mapping, Hematopoietic cell transplantation, Patient-reported outcome measures, Quality of life, Survivorship, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Long driving distances to transplantation centers may impede access to care for hematopoietic cell transplantation (HCT) survivors. As a secondary analysis from the multicenter INSPIRE study (NCT01602211), we examined baseline data from relapse-free HCT adult survivors (2 to 10 years after allogeneic or autologous HCT) to investigate the association between driving distances and patient-reported outcome (PRO) measures of distress and physical function. We analyzed predictors of elevated distress and impaired physical function using logistic regression models that operationalized driving distance first as a continuous variable and separately as a dichotomous variable (

Published
2020

20. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

Author

Hong, Sanghee, Rybicki, Lisa, Gurnari, Carmelo, Pagliuca, Simona, Zhang, Aiwen, Thomas, Dawn, Visconte, Valeria, Durrani, Jibran, Sobecks, Ronald M., Kalaycio, Matt, Gerds, Aaron T., Carraway, Hetty E., Mukherjee, Sudipto, Sekeres, Mikkael A., Advani, Anjali S., Majhail, Navneet S., Hamilton, Betty K., Patel, Bhumika J., and Maciejewski, Jaroslaw P.

Published
2022
Full Text
View/download PDF

21. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

Author

Im, Annie, Rashidi, Armin, Wang, Tao, Hemmer, Michael, MacMillan, Margaret, Pidala, Joseph, Jagasia, Madan, Pavletic, Steven, Majhail, Navneet, Weisdorf, Daniel, Abdel-Azim, Hisham, Agrawal, Vaibhav, Al-Homsi, A, Aljurf, Mahmoud, Askar, Medhat, Auletta, Jeffery, Bashey, Asad, Beitinjaneh, Amer, Bhatt, Vijaya, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Choe, Hannah, Ciurea, Stefan, Daly, Andrew, Perez, Miguel, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert, Ganguly, Siddhartha, Gergis, Usama, Hanna, Rabi, Hematti, Peiman, Herzig, Roger, Hildebrandt, Gerhard, Lad, Deepesh, Lee, Catherine, Lehmann, Leslie, Lekakis, Lazaros, Kamble, Rammurti, Kharfan-Dabaja, Mohamed, Khandelwal, Pooja, Martino, Rodrigo, Murthy, Hemant, Nishihori, Taiga, OBrien, Tracey, Olsson, Richard, Patel, Sagar, Perales, Miguel-Angel, Prestidge, Tim, Qayed, Muna, Romee, Rizwan, Schoemans, Hélène, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, Teshima, Takanori, Urbano-Ispizua, Alvaro, Van der Poel, Marjolein, Vij, Ravi, Wagner, John, William, Basem, Wirk, Baldeep, Yared, Jean, Spellman, Steve, Arora, Mukta, and Hamilton, Betty

Subjects
Adult, Cyclophosphamide, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Risk Factors, Transplantation Conditioning
Abstract

Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus

Published
2020

22. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Malki, Monzr Al, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, Weisdorf, Daniel, and Committee of the CIBMTR, Acute Leukemia

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Pediatric Cancer, Transplantation, Childhood Leukemia, Hematology, Cancer, Pediatric, Stem Cell Research, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Acute Leukemia Committee of the CIBMTR, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse [hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95% CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14) predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41). This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival (P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.

Published
2020

23. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.

Author

Buchbinder, David, Brazauskas, Ruta, Bo-Subait, Khalid, Ballen, Karen, Parsons, Susan, John, Tami, Hahn, Theresa, Sharma, Akshay, Steinberg, Amir, DSouza, Anita, Kumar, Anita, Yoshimi, Ayami, Wirk, Baldeep, Shaw, Bronwen, Freytes, César, LeMaistre, Charles, Bredeson, Christopher, Dandoy, Christopher, Almaguer, David, Marks, David, Szwajcer, David, Hale, Gregory, Schouten, Harry, Hashem, Hasan, Schoemans, Hélène, Murthy, Hemant, Lazarus, Hillard, Cerny, Jan, Tay, Jason, Yared, Jean, Adekola, Kehinde, Schultz, Kirk, Lehmann, Leslie, Burns, Linda, Aljurf, Mahmoud, Diaz, Miguel, Majhail, Navneet, Farhadfar, Nosha, Kamble, Rammurti, Olsson, Richard, Schears, Raquel, Seo, Sachiko, Beattie, Sara, Chhabra, Saurabh, Savani, Bipin, Badawy, Sherif, Ganguly, Siddhartha, Ciurea, Stefan, Marino, Susana, Gergis, Usama, Kuwatsuka, Yachiyo, Inamoto, Yoshihiro, Khera, Nandita, Hashmi, Shahrukh, Wood, William, and Saber, Wael

Subjects
Bone marrow transplantation, Lost to follow-up, Stem cell transplantation, Survivor, Adult, Aged, Child, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Survivors, Transplantation Conditioning, Transplantation, Homologous
Abstract

Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.

Published
2020

24. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Jr., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

25. Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis

Author

Maakaron, Joseph E., Zhang, Mei-Jie, Chen, Karen, Abhyankar, Sunil, Bhatt, Vijaya Raj, Chhabra, Saurabh, El Jurdi, Najla, Farag, Sherif S., He, Fiona, Juckett, Mark, de Lima, Marcos, Majhail, Navneet, van der Poel, Marjolein, Saad, Ayman, Savani, Bipin, Ustun, Celalettin, Waller, Edmund K., Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Saber, Wael, and Weisdorf, Daniel

Published
2022
Full Text
View/download PDF

28. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation

Author

Duncan, Christine N, Brazauskas, Ruta, Huang, Jiaxing, Shaw, Bronwen E, Majhail, Navneet S, Savani, Bipin N, Flowers, Mary ED, Battiwalla, Minoo, Beebe, Kristen, Dietz, Andrew C, Dvorak, Christopher C, Giller, Roger, Jacobsohn, David A, Kletzel, Morris, Martin, Paul L, Nemecek, Eneida R, Nuechterlein, Brandon, Talano, Julie-An, Pulsipher, Michael A, and Baker, K Scott

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Hematology, Cancer, Prevention, Transplantation, Heart Disease, Obesity, Pediatric, Cardiovascular, Good Health and Well Being, Adolescent, Adult, Allografts, Cardiovascular Diseases, Child, Child, Preschool, Combined Modality Therapy, Disease-Free Survival, Female, Follow-Up Studies, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Incidence, Male, Retrospective Studies, Risk Factors, Severity of Illness Index, Survival Rate, Oncology and Carcinogenesis, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24-230). 4.2% of survivors experienced at least one of the primary outcomes including coronary artery disease (0.2%), cerebrovascular accident (0.6%), cardiomyopathy (3%), and cardiac-related death (0.5%). Patients who received anthracycline chemotherapy (HR 4.67, p = 0.036) or cranial or chest radiation (HR 5.58, p

Published
2018

29. Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation

Author

Patel, Sagar S., Ahn, Kwang Woo, Khanal, Manoj, Bupp, Caitrin, Allbee-Johnson, Mariam, Majhail, Navneet S., Hamilton, Betty K., Rotz, Seth J., Hashem, Hasan, Beitinjaneh, Amer, Lazarus, Hillard M., Krem, Maxwell M., Prestidge, Tim, Bhatt, Neel S., Sharma, Akshay, Gadalla, Shahinaz M., Murthy, Hemant S., Broglie, Larisa, Nishihori, Taiga, Freytes, César O., Hildebrandt, Gerhard C., Gergis, Usama, Seo, Sachiko, Wirk, Baldeep, Pasquini, Marcelo C., Savani, Bipin N., Sorror, Mohamed L., Stadtmauer, Edward A., and Chhabra, Saurabh

Published
2022
Full Text
View/download PDF

32. Introduction

Author

Aljurf, Mahmoud, Majhail, Navneet S., Koh, Mickey B. C., Kharfan-Dabaja, Mohamed A., Chao, Nelson J., Aljurf, Mahmoud, editor, Majhail, Navneet S., editor, Koh, Mickey B.C., editor, Kharfan-Dabaja, Mohamed A., editor, and Chao, Nelson J., editor

Published
2022
Full Text
View/download PDF

37. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Author

Lin, Chenyu, primary, Tsai, Dr. Stephanie B., additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Kopmar, Noam E., additional, Dekker, Simone E., additional, Jeyakumar, Nikeshan, additional, Gupta, Vishal, additional, O'Connor, Timothy E, additional, Dykes, Kaitlyn C, additional, Ahmed, Mohamed, additional, Dholaria, Dr. Bhagirathbhai, additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Logan, Aaron C., additional, Tracy, Sean, additional, Kubiak, Michal, additional, Solh, Melhem M, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Mukherjee, Akash, additional, Battiwalla, Minoo, additional, Shaughnessy, Paul J., additional, Majhail, Navneet S., additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Ladha, Dr. Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Lee, Catherine J, additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Shah, Bijal D., additional, and Faramand, Rawan G, additional

Published
2024
Full Text
View/download PDF

39. Outpatient Administration of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma (NHL), in a Large Multi-Center Network

Author

Tees, Michael, primary, Agrawal, Tarun, additional, Martin, Casey, additional, Cox, Ms. Tonya, additional, Blunk, Betsy, additional, Billups, Rocky, additional, Bachier, Carlos R., additional, Bhushan, Vikas, additional, Cruz, Jose C Carlos, additional, Flinn, Ian W., additional, Gregory, Tara, additional, LeMaistre, Dr. C. Fred, additional, Malik, Shahbaz, additional, Mathews, John, additional, Maris, Michael, additional, Mountjoy, Luke, additional, Pantin, Jeremy, additional, Ramakrishnan, Dr. Aravind, additional, Rao, Uttam, additional, Schade, Henning, additional, Shaughnessy, Paul J., additional, Vance, Estil, additional, Zoghi, Behyar, additional, Majhail, Navneet S., additional, and Battiwalla, Minoo, additional

Published
2024
Full Text
View/download PDF

40. Carvykti (cilta-cel) Real World Outcomes across the Sarah Cannon Transplant Cell Therapy Network

Author

Gregory, Tara, primary, Blunk, Betsy, additional, Cox, Ms. Tonya, additional, Billups, Rocky, additional, Mattlin, Meredith, additional, Martin, Casey, additional, Berdeja, Jesús G, additional, Bhushan, Vikas, additional, LeMaistre, Dr. C. Fred, additional, Ramakrishnan, Dr. Aravind, additional, Shaughnessy, Paul J., additional, Majhail, Navneet S., additional, and Battiwalla, Minoo, additional

Published
2024
Full Text
View/download PDF

41. A Standardized Cell Dose to Optimize Unrelated Donor Peripheral Blood Stem Cell (PBSC) Collections: A Prospective Study between the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) and the National Marrow Donor Program (NMDP)

Author

Rao, Uttam, primary, Blunk, Betsy, additional, Martin, Casey, additional, Stefanski, Dr. Heather E., additional, Devine, Steven M., additional, Koretzky, Lindsey, additional, Bhushan, Vikas, additional, Billups, Rocky, additional, LeMaistre, Dr. C. Fred, additional, Gregory, Tara, additional, Pantin, Jeremy, additional, Ramakrishnan, Dr. Aravind, additional, Shaughnessy, Paul J., additional, Tees, Michael, additional, Majhail, Navneet S., additional, and Battiwalla, Minoo, additional

Published
2024
Full Text
View/download PDF

42. Centralized Data Management Model within the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN)- Process, Challenges and Benefits

Author

Blunk, Betsy, primary, Zambrano, Hector, additional, Billups, Rocky, additional, Majhail, Navneet S., additional, Bosch, Connie, additional, Culver, Jennifer, additional, Sinnema, Julie, additional, Wood, Mary, additional, Younger, Leslie, additional, Olivarez, Angelica, additional, Turner, Veloria, additional, Bays, Nora Kristin, additional, Hatley, Sarah B L, additional, Jordan, Tiffany, additional, and Cox, Tonya, additional

Published
2024
Full Text
View/download PDF

44. Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Author

Rao, Uttam, primary, Blunk, Betsy, additional, Bachier, Carlos R., additional, Bhushan, Vikas, additional, Cruz, Jose C Carlos, additional, Elayan, Mohammed M., additional, Flinn, Ian W., additional, Gregory, Tara, additional, LeMaistre, Dr. C. Fred, additional, Majhail, Navneet S., additional, Malik, Shahbaz, additional, Martin, Casey, additional, Blade, Gabrielle, additional, Maris, Michael, additional, Mathews, John, additional, Mountjoy, Luke, additional, Pantin, Jeremy, additional, Ramakrishnan, Dr. Aravind, additional, Shaughnessy, Paul J., additional, Tees, Michael, additional, Vance, Estil, additional, Zoghi, Behyar, additional, and Battiwalla, Minoo, additional

Published
2024
Full Text
View/download PDF

45. Remote Patient Monitoring (RPM) Technology with Centralized Virtual Nurse Monitoring for Safe Delivery of Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapy across Multiple Sarah Cannon Transplant and Cellular Therapy Network Programs

Author

Cox, Tonya, primary, Carelock, Trista, additional, Zahradka, Nicole, additional, Pugmire, Juliana, additional, Wilkes, Matt, additional, Campo, Rebecca, additional, Garber, Sarah, additional, Yates, Megan, additional, Perez, Meredith, additional, Husband, Mary, additional, Martin, Casey, additional, Blunk, Betsy, additional, Billups, Rocky, additional, LeMaistre, Dr. C. Fred, additional, Pantin, Jeremy, additional, Ramakrishnan, Dr. Aravind, additional, Shaughnessy, Paul J., additional, Tees, Michael, additional, Majhail, Navneet S., additional, and Battiwalla, Minoo, additional

Published
2024
Full Text
View/download PDF

46. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author

O'Connor, Timothy E, primary, Lin, Chenyu, additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Faramand, Rawan G, additional, Kopmar, Noam E., additional, Dykes, Kaitlyn C, additional, Jeyakumar, Nikeshan, additional, Dekker, Simone E., additional, Gupta, Vishal, additional, Ahmed, Mohamed, additional, Logan, Aaron C., additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Tracy, Sean, additional, Kubiak, Michal, additional, Mukherjee, Akash, additional, Majhail, Navneet S., additional, Battiwalla, Minoo, additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Shaughnessy, Paul J., additional, Ladha, Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Solh, Melhem M, additional, Lee, Catherine J., additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Tsai, Dr. Stephanie B., additional, and Dholaria, Dr. Bhagirathbhai, additional

Published
2024
Full Text
View/download PDF

49. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Aljurf, Mahmoud, Nishihori, Taiga, Marsh, Rebecca, Burroughs, Lauri M., Majhail, Navneet, Al-Homsi, A. Samer, Al-Kadhimi, Zaid S., Bar, Merav, Bertaina, Alice, Boelens, Jaap J., Champlin, Richard, Chaudhury, Sonali, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, El-Jawahri, Areej, Fanning, Suzanne, Fraint, Ellen, Gergis, Usama, Giralt, Sergio, Hamilton, Betty K., Hashmi, Shahrukh K., Horn, Biljana, Inamoto, Yoshihiro, Jacobsohn, David A, Jain, Tania, Johnston, Laura, Kanate, Abraham S., Kansagra, Ankit, Kassim, Adetola, Kean, Leslie S., Kitko, Carrie L., Knight-Perry, Jessica, Kurtzberg, Joanne, Liu, Hien, MacMillan, Margaret L., Mahmoudjafari, Zahra, Mielcarek, Marco, Mohty, Mohamad, Nagler, Arnon, Nemecek, Eneida, Olson, Timothy S., Oran, Betul, Perales, Miguel-Angel, Prockop, Susan E., Pulsipher, Michael A., Pusic, Iskra, Riches, Marcie L., Rodriguez, Cesar, Romee, Rizwan, Rondon, Gabriela, Saad, Ayman, Shah, Nina, Shaw, Peter J., Shenoy, Shalini, Sierra, Jorge, Talano, Julie, Verneris, Michael R., Veys, Paul, Wagner, John E., Savani, Bipin N., Hamadani, Mehdi, and Carpenter, Paul A.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results